Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application PCT/US2018/012672, filed Jan 5, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,994,020 | Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping In force · Low confidence | Avidity Biosciences LLC | In force | Low confidence | ||
| US 11,179,472 | Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping In force · Low confidence | Avidity Biosciences LLC | In force | Low confidence | ||
| US 11,311,627 | Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping In force · Low confidence | Avidity Biosciences, Inc. | In force | Low confidence | ||
| US 11,400,163 | Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping In force · Low confidence | Avidity Biosciences, Inc. | In force | Low confidence | ||
| US 12,064,483 | Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping In force · Low confidence | Avidity Biosciences, Inc. | In force | Low confidence | ||
| Application 18/770,359 | Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping Pending Not granted | Avidity Biosciences, Inc. | Pending | Not granted | ||
| Application 19/031,231 | Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping Pending Not granted | Avidity Biosciences, Inc. | Pending | Not granted | ||
| Application 19/312,209 | Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping Pending Not granted | Avidity Biosciences, Inc. | Pending | Not granted |
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Avidity Biosciences, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.